Market PenetrationEkterly is well positioned as the first oral on-demand option for HAE, expected to broaden and quickly penetrate the market.
Product LaunchEarly US uptake confirms broad patient and physician enthusiasm and validates management's pre-launch investment in commercial infrastructure.
Sales PerformanceEkterly numbers are better than expected, generating $1.4mn sales by the end of July, which is twice the forecasted amount by several analysts.